Fabian Theis Announces New Health AI Career Opportunities

Dec 22, 2025, 4:11 AM

Hover over text to view sources

Fabian Theis, the Director of the Institute of Computational Biology and a Professor at the Technical University of Munich (TUM), recently shared exciting news regarding new career opportunities in Health AI at the Helmholtz Munich Computational Health Center. This initiative aims to attract outstanding researchers to a vibrant ecosystem that integrates computational biology, artificial intelligence (AI), and biomedical research, fostering collaboration across various disciplines.

The Helmholtz Munich Computational Health Center is currently hiring for several key positions:.

Principal Investigators in Health AI and AI Foundations: These roles will focus on shaping the next generation of AI in biomedicine and AI methods research, with ample opportunities for collaboration across Helmholtz Munich and clinical partners.

Health AI Fellows (Independent Postdoctoral Fellowships): This fellowship is designed to support early-career researchers in establishing an independent research profile in Health AI and computational biomedicine.

Clinical AI Consultants (AI-Clinic Interface): This new track aims to bridge clinical needs with AI-driven innovations, ideal for clinically trained professionals who wish to work closely with existing AI consulting teams within the Munich Medical Alliance M1.

The announcement comes as Theis continues to lead significant advancements in the field of computational biology. His research primarily focuses on applying AI and machine learning to decode the complexities of human cells, particularly through single-cell sequencing. This work is part of larger international initiatives, such as the Human Cell Atlas project, which aims to create a comprehensive reference map of all human cells, enhancing our understanding of health and disease.

Theis's contributions to the field have not gone unnoticed; he has received numerous accolades, including the prestigious Gottfried Wilhelm Leibniz Prize in 2023 and the ISCB Innovator Award, recognizing his significant advancements in computational biology and AI-driven biomedical research. His leadership at Helmholtz Munich is pivotal, as he coordinates Helmholtz AI and plays a crucial role in various national and European AI initiatives, further solidifying his status as a leading figure in the field.

The collaboration between Helmholtz Munich and the Eric and Wendy Schmidt Center at the Broad Institute of MIT and Harvard exemplifies the growing intersection of AI and health research. This partnership aims to leverage machine learning methods to address major challenges in biomedical research, highlighting the need for advanced computational tools to keep pace with the explosion of biological data generated in recent years.

The new career opportunities at Helmholtz Munich not only aim to attract top talent but also emphasize the importance of interdisciplinary collaboration in advancing healthcare solutions. Theis encourages individuals passionate about shaping the future of Health AI and computational medicine to apply or share these opportunities within their networks, fostering a community dedicated to transformative biomedical research.

As the field of Health AI continues to evolve, the initiatives led by Theis and his team at Helmholtz Munich are set to play a crucial role in driving innovation and improving healthcare outcomes through data-driven approaches. The future of medicine is increasingly data-based, and the opportunities at the Computational Health Center represent a significant step towards realizing this vision.

In conclusion, the announcement of new career opportunities in Health AI at Helmholtz Munich reflects a commitment to advancing the integration of AI in biomedicine. With a focus on collaboration and innovation, these positions are poised to attract talented researchers eager to contribute to the future of healthcare and computational medicine.

Brain Activity and Food Preoccupation in Tirzepatide Users

Recent research has revealed insights into brain activity related to food preoccupation in individuals using tirzepatide, a medication for type 2 diabetes. A case study highlighted how this drug temporarily suppressed signals in the brain's reward center, potentially offering new avenues for treating eating disorders. However, the effects were not long-lasting, indicating the need for further research.

Telix Pharmaceuticals Updates on Precision Medicine Portfolio

Telix Pharmaceuticals has announced significant updates regarding its precision medicine portfolio, including positive results from a Phase 3 study of TLX591-CDx in China, and progress on NDA resubmissions for TLX101-CDx and TLX250-CDx in the US These developments are expected to enhance treatment options for prostate cancer and glioma patients.

Risks of AI Recommending Thalidomide to Pregnant Women

The use of AI models like ChatGPT for medical advice raises significant concerns, particularly regarding the recommendation of harmful drugs like thalidomide to pregnant women. Studies show that these models can be manipulated to suggest unsafe medications, highlighting the need for caution and human oversight in AI-generated health information.

Stanford Study Explains mRNA Vaccine-Linked Myocarditis Mechanism

A Stanford Medicine study has identified the immune response mechanisms that may lead to myocarditis in rare cases following mRNA COVID-19 vaccination. The research highlights the roles of specific cytokines and suggests potential preventive measures using genistein, a compound derived from soybeans.

Daily Wonder: Enhancing Health Through Awe

Experiencing wonder daily can significantly improve mental and physical health. Engaging with art, nature, and mindful practices fosters awe, which has been shown to reduce stress, enhance well-being, and deepen connections with others.